Loading…
← CockpitCompetitor Analysis › 688506.SS Sichuan Biokin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Sichuan Biokin Pharmaceutical Co., Ltd. Class A688506.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Biotech developing antibody-drug conjugates (ADCs) for cancer, with global licensing deals including one with Merck.

Momentum strong 63
Mkt cap
$14.9B
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$63.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.5 pp
WACC 6.4%
Hurdle
n/a
no reverse DCF
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥238.30
1D+2.9%
1W-6.8%
1M-5.9%
3M-22.9%
6M-7.3%
YTD-26.2%
1Y-34.2%
ATR %5.5%
52w lowhigh41.0% off high

What Sichuan Biokin Pharmaceutical does

Biotech developing antibody-drug conjugates (ADCs) for cancer, with global licensing deals including one with Merck.

Revenue arrives mainly through licensing: partners pay upfront and milestone amounts on its antibody-drug conjugates, drugs that combine a cancer-targeting antibody with a toxin, so earnings come in lumps when a deal is signed or a trial milestone is reached.

Products and services

  • ADC oncology pipeline
  • Licensed/partnered ADC assets

Customers

  • Global pharma partners (licensing); cancer patient

Where it sits in the supply chain

  • Biotechnology
  • Oncology ADC drug development
  • Antibody-drug conjugate (ADC) cancer…

What could go right

  • Global ADC licensing/milestone payments
  • Oncology drug approvals

What could go wrong

  • Clinical-trial failure risk
  • Dependence on partner milestone payments

Moat: narrow (IP / patents). Proprietary ADC technology platform validated by large global licensing deals, including with Merck.

Headquarters: Chengdu, Sichuan, China · Founded: 1996 · Employees: 3,198

Named competitors

Sichuan Biokin Pharmaceutical at a glance

Size Sichuan Biokin Pharmaceutical (688506.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $14.9B, the 148th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥238.30 on 18 Nov 2026.

Performance Over six months the shares fell 7.3%, against +4.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 14.5% over the last twelve months (peer median +18.9%); the operating margin is -42.7% (peer median 23.1%).

Valuation It trades at 39.2× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 21).

Capital Return on invested capital runs 19.5 points below its cost of capital (6.4% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 105688506.SS 94
Six months, rebased to 100: Sichuan Biokin Pharmaceutical against the median of its 20 peers (local-currency closes).

Sichuan Biokin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.55BCN¥2.52BCN¥5.82BCN¥557MCN¥695M
Revenue growth—-57%+945%-20%—
Gross profitCN¥2.32BCN¥2.20BCN¥5.50BCN¥284MCN¥420M
EBITDAn/a-CN¥697MCN¥3.76B-CN¥732M-CN¥269M
Net income-CN¥1.26B-CN¥1.05BCN¥3.71B-CN¥780M-CN¥282M
Free cash flow-CN¥1.95B-CN¥1.06BCN¥4.01B-CN¥697M-CN¥293M
Capital expenditureCN¥914MCN¥264MCN¥83.9MCN¥81.9MCN¥34.6M
Total debtCN¥6.67BCN¥3.82BCN¥2.18BCN¥730MCN¥573M

Quarterly statements and history in the cockpit →

Sichuan Biokin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%0005386446IPNORNAVJAZZSOBILAURUSLABSEXELASND6990ZYDUSLIFEDRREDDY1177RECTORNTPHARM1801600436ALNY688506.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Sichuan Biokin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%0×20×40×0005386446IPNORNAVJAZZSOBILAURUSLABSASND6990ZYDUSLIFE4507DRREDDYTORNTPHARM1801600436MANKINDALNY688506.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sichuan Biokin Pharmaceutical is the large dot.

Sichuan Biokin Pharmaceutical competitors and peer comparison

Head to head with its named competitors (688506.SS vs 4568.T vs PFE vs ABBV)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Sichuan Biokin Pharmaceutical 688506.SS$14.9B-7%+14%-43%39.2×n/a
Daiichi Sankyo 4568.T$31.4B+8%+17%13%2.1×7.6%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
AbbVie ABBV$506B+35%+11%36%8.7×-0.1%

How Sichuan Biokin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sichuan Biokin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure688506.SSPeer medianRank in peer set
1-month return-5.9%+6.1%3rd lowest of 21
6-month return-7.3%+4.6%2nd lowest of 21
Distance from 52-week high-41.0%-6.8%2nd lowest of 21
Revenue growth (TTM)+14.5%+18.9%9th lowest of 21
Operating margin-42.7%23.1%lowest of 21
EV / Sales39.2×6.0×2nd most expensive of 21
ROIC minus cost of capital-19.5 pp+7.9 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%39.2×n/an/a
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%2.1×-0.2%+4.7%
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%19.0×23.7%+94.8%
Ipsen IPN.PAFrance$14.8B+1%+14%30%3.1×-6.7%+7.2%
Orion ORNAV.HEFinland$15.7B+41%+34%38%6.5×-6.2%+11.7%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%4.0×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%5.6×-2.1%+13.1%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%16.4×51.2%+7.3%
Exelixis EXELUnited States$16.7B+37%+9%40%6.4×-3.8%+18.6%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%11.7×19.2%+152.4%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%41.4×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%4.3×n/an/a
Shionogi & 4507.TJapan$17.6B+3%+46%29%4.9×0.2%+11.0%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%3.5×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%2.6×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%4.5×1.1%+12.6%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%10.7×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%7.3×11.6%+26.8%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%9.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%7.2×28.6%+18.1%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%3.9×0.5%+49.8%

Questions

Who are Sichuan Biokin Pharmaceutical's main competitors?
Named competitors: Daiichi Sankyo (4568.T), Pfizer (Seagen) (PFE), AbbVie (ImmunoGen) (ABBV). The cockpit's measured peer set (industry) also includes Yunnan Baiyao (000538.SZ), PharmaEssentia (6446.TW), Ipsen (IPN.PA), Orion (ORNAV.HE), Jazz Pharmaceuticals Public (JAZZ), Swedish Orphan Biovitrum (SOBI.ST).
Is Sichuan Biokin Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 39.2× against a peer median of 6.0×, 2nd most expensive of 21 in its peer set.
How has Sichuan Biokin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -7.3% against +4.6% for the median peer; over one year -34.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.